Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
Conclusion.Both oncologists and neurologists need to be aware of signs and symptoms of serious but uncommon neurologic irAEs associated with checkpoint inhibitors. Prompt diagnosis and management using an established algorithm are critical to minimize serious complications from these neurologic irAEs.Implications for Practice.With increasing use of checkpoint inhibitors in cancer, practicing oncologists need to be aware of the potential risk of neurologic immune‐related adverse events and be able to provide prompt treatment of this uncommon, but potentially serious, class of adverse events. We summarize neurologic adverse events related to nivolumab alone or in combination with ipilimumab in patients with advanced melanoma from 12 studies and examine in depth 6 cases of encephalitis. We also provide input and guidance on the existing neurologic adverse events management algorithm for nivolumab and ipilimumab.
Source: The Oncologist - Category: Cancer & Oncology Authors: James Larkin, Bartosz Chmielowski, Christopher D. Lao, F. Stephen Hodi, William Sharfman, Jeffrey Weber, Karijn P. M. Suijkerbuijk, Sergio Azevedo, Hewei Li, Daniel Reshef, Alexandre Avila, David A. Reardon Tags: Review, Melanoma and Cutaneous Malignancies Source Type: research
More News: Brain | Cancer | Cancer & Oncology | Databases & Libraries | Encephalitis | Epidemiology | Headache | Melanoma | Men | Meningitis | Migraine | Neurology | Skin Cancer | Study | Yervoy